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Cats  may  be  infected  by  heartworm,  Diroﬁlaria  immitis,  through  mosquito  bites.  They  can
develop  severe  heartworm  disease  when  infective  D. immitis  larvae  migrate  and  develop
into adults  in  the  pulmonary  vasculature  or  other  tissues.  As  there  is  no  curative  treatment
for feline  heartworm  infection,  the monthly  administration  of preventative  treatment  is  rec-
ommended  in  endemic  areas.  Three  controlled,  blinded  laboratory  studies  were  conducted
to evaluate  the  preventative  efﬁcacy  of  BROADLINE®, a novel  combination  of  ﬁpronil,  (S)-
methoprene,  eprinomectin,  and  praziquantel  against  D. immitis  in  cats.  In each  study,  28
cats  were  inoculated  with  approximately  100  (studies  1 and  2)  or 40 (study  3)  infective  third
stage D. immitis  larvae  by  subcutaneous  injection,  thirty  days  prior  to treatment.  The  larvae
were  from  recent  ﬁeld isolates  from  naturally  infected  dogs  from  three  distinct  geographic
areas (two  in  the  USA  and  one  in Europe).  In each  study,  the  cats were  allocated  randomly
to two  study  groups  of  14  cats  each.  The  control  group  remained  untreated.  On  Day 0,  each
cat in  the treated  group  received  one  topical  application  of  the  novel  topical  formulation,
delivering  the  minimum  intended  dose  of  0.5 mg  of  eprinomectin  per  kilogram  of  body
weight.  At 6 months  after  infection,  all cats were  humanely  euthanized  and  examined  for
adult D. immitis.  Across  all  three  studies,  28  (68%)  of  the  41  untreated  cats  harbored  one  or
more  heartworms,  while  100%  of the 42  treated  cats  remained  free  of  heartworm  infection,
demonstrating  the  100%  preventive  efﬁcacy  of BROADLINE® against  D. immitis  in cats.  The
treatment  was well  tolerated  and  no  health  abnormality  was  observed  in  any  treated  cat.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
Y-NC-NB∗ Corresponding author at: Merial Limited, 115 Transtech Drive,
thens, GA 30601, USA. Tel.: +1 706 552 2445; fax: +1 706 552 2451.
E-mail address: christine.baker@merial.com (C.F. Baker).
http://dx.doi.org/10.1016/j.vetpar.2014.02.039
304-4017/© 2014 The Authors. Published by Elsevier B.V. This is an open acce
icenses/by-nc-nd/3.0/).D  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
As observed in domestic dogs (Genchi et al., 1991;
Guerrero et al., 1992), coyotes (Willingham and Gehrt,
2010), or within mosquito populations, the incidence of
Diroﬁlaria immitis (heartworm) infection is highest in the
tropical and sub-tropical regions of the world where high
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density populations of reservoir and intermediate hosts
coexist and perpetuate the life cycle. Even if less recep-
tive than dogs, cats can also be infected by D. immitis in
the same endemic areas (Patton and McCracken, 1991;
Ryan and Newcomb, 1995; Miller et al., 2000; Levy et al.,
2003). Because they are not the natural host for this para-
site, they are less susceptible to patent infection than dogs
and their infection rate has been estimated to be approx-
imately 9–18% that of dogs in the same endemic areas
(Venco et al., 2011). The presence of D. immitis in cats
results in marked immunological reactions that will often
kill the parasite before or after it reaches its ﬁnal destina-
tion in the pulmonary vessels. This strong immunological
reaction may  also cause severe pathology in the host, espe-
cially in response to the death of the adult pulmonary stage
of D. immitis. Heartworm disease in cats may  present with
episodic, chronic or acute clinical signs that may  include
coughing, vomiting, dyspnea, lethargy, anorexia or weight
loss, or severe respiratory distress, convulsions and sud-
den death in the most severe cases, which may  occur even
in cats harboring a single heartworm (McCall et al., 1992;
Jacobs et al., 1994; Dillon, 1995; Atkins et al., 2000; Litster
and Atwell, 2008; McCall et al., 2008). High risk surgi-
cal removal is the only potential treatment of pulmonary
stages of D. immitis in cats. The severity of heartworm dis-
ease in cats leaves chemoprophylaxis as the only safe and
effective option to protect cats from the adverse effects of
adult heartworms.
Eprinomectin is a macrocyclic lactone that has proved to
be highly effective as a topical formulation against internal
and external parasites of cattle (Shoop et al., 1996; Holste
et al., 1997; Pitt et al., 1997; Williams et al., 1997; Holste
et al., 1998; Watson and Forbes, 2000; Rehbein et al., 2005).
Preliminary studies conﬁrmed the excellent bioavailabil-
ity and systemic activity of eprinomectin in cats following
topical application (Kvaternick et al., 2014). The present
studies were conducted to evaluate the efﬁcacy of a sin-
gle topical treatment of eprinomectin at the minimum
intended dose of 0.5 mg/kg body weight in a novel topical
combination with ﬁpronil, (S)-methoprene and praziquan-
tel, Broadline®, to prevent heartworm disease in cats.
2. Materials and methods
2.1. Study design and randomization
Three controlled, blinded laboratory studies were con-
ducted, two in the United States and one in France, with
similar designs, as summarized in Table 1. The 3 stud-
ies were designed in accordance with the “International
Cooperation on Harmonisation of Technical Requirements
for Registration of Veterinary Medicinal Products” (VICH)
guideline (GL) 7, “Efﬁcacy of Anthelmintics: General
Requirements” (Vercruysse et al., 2001); VICH GL 20,
“Efﬁcacy of Anthelmintics: Speciﬁc Recommendations for
Felines” (Vercruysse et al., 2002); as well as with the
“World Association for the Advancement of Veterinary
Parasitology (WAAVP) guidelines for evaluating the efﬁ-
cacy of anthelmintics for dogs and cats” (Jacobs et al.,
1994). All studies were also conducted in compliance withitology 202 (2014) 49–53
local Institutional Animal Care and Use Committee require-
ments, and with International laws and ethics.
Twenty-eight cats (14 females and 14 males) were
included in each study. Fourteen cats were assigned to each
control and treatment group using a randomized block
design based on body weight within sex in studies 1 and
2 and on sex in study 3. All personnel collecting animal
health and efﬁcacy data were blinded to the treatment.
2.2. Study animals
All study subjects were healthy purpose-bred lab-
oratory cats, born and raised in a mosquito-protected
environment. For completeness, all cats were tested for the
presence of D. immitis antigens before infection and on Day
89 or 90 using an ELISA test (DiroCHECK®, Synbiotic Cor-
poration, San Diego, CA, USA in studies 1 and 2; SNAP 4Dx,
IDEXX Laboratories, Portland, Maine, USA in study 3). Any
positive test result up to Day 90 (4 months after infection)
would indicate that the infection had been acquired before
the study. The cats had never been treated with macrocyclic
lactones and had not been reared by queens treated with
macrocyclic lactones.
2.3. Animal health
All animals had a physical examination conducted by
a veterinarian to detect any health abnormality prior to
infection. Health observations were conducted, at hourly
intervals for four hours after treatment, and daily through-
out the studies to detect the presence or absence of any
health abnormality or adverse treatment reaction.
2.4. D. immitis inoculations
On Study Day −30, all cats were inoculated by sub-
cutaneous injection of approximately 100 (study 1 and
2) or 40 (study 3) infective third stage larvae (L3). For
studies 1 and 2, the inoculation was performed immedi-
ately after the D. immitis larvae had been processed from
mosquitoes infected with laboratory isolates originated in
the USA (Georgia and Michigan, respectively). For study 3,
the larvae were processed from mosquitoes in Italy and
transferred to the study site under refrigerated conditions
for approximately 5 h before infections were conducted.
2.5. Treatment
Control cats were not treated. On Study Day 0, each cat
in the treated group received a single topical application of
the novel combination product at the minimum intended
dose of 0.12 mL/kg body weight (bw), delivering 10 mg/kg
bw ﬁpronil, 12 mg/kg bw (S)-methoprene, 0.5 mg/kg bw
eprinomectin and 10 mg/kg bw praziquantel.
2.6. Efﬁcacy evaluation: heartworm countsAt approximately 6 months after infection, based on
local logistic availability of personel, on Day 150 (stud-
ies 1 and 2) or Day 159 (study 3), all cats were humanely
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Table  1
Study design: location, animals, inoculation, treatment and necropsy timing to assess the efﬁcacy of Broadline® spot on against Diroﬁlaria immitis in cats.
Study number (location) Age of cats
at
inoculation
D. immitis
isolate
origin
Inoculation
(Day −30)
Cat number
and sex
Pre-treatment
body weight
range
Treatmentc (Day 0) Necropsy for
recovery and
counts of adult
D. immitis
1 (USA) 3.0–4.0
months
Georgia,
USA
∼100 L3a 14 male
and 14
female
1.5–2.8 kg Topical application of
0.12 mL/kg bodyweight
Broadline®
Day 150
2  (USA) 3.2–4.4
months
Michigan,
USA
∼100 L3 14 male
and 14
female
1.7–3.4 kg Day 150
3  (France) 5.1–5.8
months
Italy ∼40 L3 14 male
and 13
femaleb
1.0–4.0 kg Day 159
a L3 = Infective third stage larvae of D. immitis.
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c On Day 0, in each study, the control group remained untreated and th
uthanized, and necropsied for the recovery of adult heart-
orms. The site of infection and the abdominal and thoracic
avities were opened and examined for the presence of
ny heartworm. The anterior and caudal vena cavae were
lamped with forceps and the heart, lungs and liver were
emoved as one unit. The posterior vena cava, precava,
ight atrium, right ventricle, pulmonary arteries (including
ithin the lungs) and major hepatic veins were carefully
issected and the heartworms were collected and counted
y personnel unaware of treatment assignment.
.7. Data analysis
Total counts of D. immitis worms were transformed to
he natural logarithm of (count + 1) for calculation of geo-
etric means for each group. Efﬁcacy was determined by
alculating the percent efﬁcacy as [(C − T)/C] × 100, where
 is the geometric mean among untreated controls and T
s the geometric mean among treated animals. To compare
he geometric means of the two groups, the mean of the
og counts of the treated group was compared to the mean
f the log counts of the untreated control group using an
-test adjusted for the allocation blocks used to random-
ze the cats to the treatment groups. The mixed procedure
n SAS® version 9.1.3 was used for the analysis, with the
reatment group listed as a ﬁxed effect and the allocation
lock as a random effect. All testing was two-sided at the
.05 signiﬁcance level.
. Results
In study 3, one female cat was removed before treat-
ent due to health concerns, leaving only 13 cats (7 males
nd 6 females) in the untreated control group. No adverse
eactions to the treatment were observed in any cat during
he studies. The results of heartworm antigen tests con-
ucted up to Day 89 or 90 were all negative, showing no
race of exposure to D. immitis prior to the infection on Day
30.
The results of the heartworm counts conducted at
pproximately 6 months after infection and their analy-
es are presented in Table 2. Thirteen of the 14 control catsr health reasons.
d group was treated with the minimum dose of the novel formulation.
in study 1, and 10 of the 14 control cats in study 2 had
between 1 and 17 and 2 and 25 adult heartworms, respec-
tively, and the remaining control cats had no evidence of
heartworm infection in these 2 studies. In study 3, 5 of the
13 control cats had between one and four adult D. immitis
and no worms were recovered from the remaining 8 con-
trol cats. In all 3 studies, no heartworm was recovered from
any treated cat, demonstrating a 100% treatment efﬁcacy.
In addition, the heartworm counts were signiﬁcantly dif-
ferent between the control and treated group in each study
(Table 2).
4. Discussion
In all three studies, the necropsies were conducted at 6
months after infections, when all larvae were expected to
have reached their ﬁnal location and developed into adults
(McCall et al., 1992). Inoculation with approximately 100
infective L3 D. immitis per cat led to persistent heartworm
infection in 13 out of 14 (92.9%) control cats in study 1, and
10 out of 14 (71.4%) control cats in study 2, representing
an overall infection rate of 82.1% in control cats for these
two studies combined. These results are consistent with
infection rates reported in previous studies of similarly
infected cats (McTier et al., 1992; Paul et al., 1992; Stewart
et al., 1992; McTier et al., 2000). The geometric means of
the number of heartworms per control cat, 4.8 and 3.4 in
studies 1 and 2 respectively, are also comparable to pre-
vious reports, conﬁrming that the two  heartworm isolates
used in these studies were valid and capable of establishing
patent infection in cats. The USA isolates utilized in stud-
ies 1 and 2 originated from naturally infected dogs from
Georgia and Michigan and had been validated and then
maintained in the laboratory for less than three years. For
study 3, there was no preliminary validation and the L3
D. immitis were obtained from mosquitoes fed on recent
isolates from naturally infected dogs from Italy. The geo-
graphic and spatial separation of these three heartworm
isolates was  designed to provide genetic diversity. Due to
limited availability, only approximately 40 L3 were used
to infect each cat in Study 3. Despite the lower inocula-
tion load than in the other two  studies, ﬁve of the thirteen
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Table 2
Ranges and analyses of Diroﬁlaria immitis countsa obtained at necropsy in the three heartworm efﬁcacy studies.
Study & group Percentage (number)
of cats with 1 or more
D. immitis
D. Immitis
number per cat
(range)
Geo meanb Percent efﬁcacy
of Broadline®(c)
P-valued
Study 1 Control 92.9% (13) 1–17 4.8
Treated 0% (0) 0 0.0 100.0 <0.001
Study 2 Control 71.4% (10) 2–25 3.4
Treated 0% (0) 0 0.0 100.0 <0.001
Study  3 Control 38.5% (5) 1–4 0.6 0.013
Treated 0% (0) 0 0.0 100.0
a Logarithms of the (counts + 1) were analyzed using SAS version 9.1.3. Mixed procedure with treatment group ﬁxed effect and replicate random effect.
b Geometric mean computed by taking the anti-logarithm of the mean of the log counts and then subtracting 1.
eans of c Percent efﬁcacy = 100 × [(C – T)/C], where C and T are the geometric m
d Two-sided probability values.
(38.5%) control cats were infected with D. immitis on Day
159, with individual heartworm counts ranging from 2 to
4 heartworms in four control cats, and a single heartworm
in the ﬁfth control cat. The lower worm burden per control
cat in study 3 compared to study 1 and 2 may  have reﬂected
the lower number of larvae used for infection, similarly to
the 1.34 geometric mean number of heartworms reported
by Genchi et al., when using 50 L3 per cat (Genchi et al.,
2004), although control cats had a higher rate of infection
(11/12 or 91.7%) in that report than the control cats in study
3. The longer transfer time before cat infection and the con-
ditions of conservation of the L3 collected from mosquitoes
and cat infection may  have contributed to the lower infec-
tion rate observed in Study 3. Heartworm infection rates
of cats are notoriously variable, even when using higher
challenges. In one of the three studies reported by McTier
et al. (1992), four out of nine cats, each infected with 100 L3,
did not have any heartworm recovered and the geometric
mean of heartworm counts was consistent with that seen
in study 3. While the infection rates of the control groups
in the three studies did vary, none of the cats treated with
Broadline® had any heartworm recovered, demonstrating
a uniform 100% efﬁcacy of the eprinomectin component of
this novel combination product, even when dosed at the
minimum therapeutic dose. Studies 1 and 2 fully satisﬁed
the VICH and WAAVP guidelines for adequate infection of
control cats and the demonstration of 100% preventive efﬁ-
cacy of Broadline® against D. immitis. Across the 3 studies,
28 (68%) of the 41 untreated cats harbored one or more
heartworms and 100% of the 42 treated cats remained free
of heartworm infection.
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